<<<<<(1) Keep in mind that the study was looking at breast cancer or melanoma. They are also running a post-marketing study in head/neck cancers. After that, they plan on doing studies in colon, prostate and gastric cancers. There are other potential indications in gynecological cancers.>>>>>
SNLB has only been accepted mainstream in Breast, and to a lessor degree melanoma currently. I am basically stay conservatively grounded for the moment. I understand this could be key emphasasis on could be the game changer to adopt mainstream SNLB in other indications. Yes, I am extremely excited to hear head and neck data.--At last update no misses compared to axillary radical lymph node pathology.===true 0% false negative
<<<<<<(2) I think it will do somewhat better sales than you expect considering Cardinal Health is going to be pushing the product. It's a high margin product. I remember seeing estimates of about $300-400/dose.>>>>>
Probably better sales, I only offer with almost absolute certainty my belief of conservative uptake. Yes the model is awesome with the distribution model already in place. The sulfur colloid market will be a very easy market to penetrate. The trick is to convert blue dye only surgeons, and create adoption of other tumor types. (Just getting a little speculative on surgeon acceptance into tumor types that are not established) Keep in mind I'm only providing a peak into the easier U.S. breast modeling. That said we are looking at approx. 700 million market cap on diluted basis. I also use a more conservative early estimates of $200 dosing to keep myself grounded a bit. Also true that Neoprobe would be cash flow positive or very close on probe business alone without R&D lymphoseek.
<<<<(3) After the recent study featured in the NYTimes about breast cancer and SNLM, don't you expect the number of procedures to increase? >>>>>>>
Possibly, but I think widespread adoption pretty close to already mainstream at this point. There are other specific reasons for patients that are not candidates for SNLB
